# PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia

> **NCT00362544** · PHASE4 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 30 (—)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Ambisome

## Key facts

- **NCT ID:** NCT00362544
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 30 (—)
- **Last updated:** 2015-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362544, "PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00362544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*